Viking Therapeutics, Inc.

VKTX Healthcare Biotechnology

In the quarter to June 2026, EPS fell 89.7% and free cash flow fell 166.0%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

25.17 2.20 −8.04%
Market cap
$3.5B
P/E
0.0×
Fwd P/E
—
Dividend yield
—
F-score
n/a
Altman Z
n/a
Beneish M
n/a
Dividend safety
n/a
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
ROE
(88.85%) (70.04%) (47.34%) (29.23%)

+8 more TTM periods

ROA
(79.24%) (64.04%) (44.29%) (28.31%)
ROIC
0.00% 0.00% 0.00% 0.00%
Return on Tangible Assets
(131.11%) (94.11%) (56.29%) (33.31%)
Free Cash Flow per Share
(3.60) (2.94) (2.47) (2.00)
Free Cash Flow
(418.44) (340.33) (278.68) (224.58)
Other line items

Show all line items

Columns are period end dates